Navigation Links
St. Jude Researchers Identify Key Genetic Trigger of Acute Myeloid Leukemia
Date:11/27/2007

N-Myc gene lives a double life, triggering cancer when it works with the growth-promoting protein IL-3 and causing cell suicide in the absence of IL-3

MEMPHIS, Tenn., Nov. 27 /PRNewswire-USNewswire/ -- A gene called N-Myc leads a double life in certain white blood cells when it is overexpressed, helping to trigger acute myeloid leukemia (AML) under some conditions while triggering apoptosis, or cell suicide, under other conditions, according to results of a mouse study done by investigators at St. Jude Children's Research Hospital.

"Since N-Myc overexpression frequently occurs in human AML as well, this discovery gives researchers an important insight into N-Myc's role in human AML," said Gerard Grosveld, Ph.D., chair of the St. Jude Department of Genetics and Tumor Cell Biology. "It also might contribute to new strategies for treating this leukemia or disrupting this gene's ability to cause it." Grosveld is senior author of a report on this work that appears in the Nov. 15 issue of "Cancer Research."

The researchers showed that artificially forcing overexpression of N-Myc in bone marrow cells of mice strongly promotes AML; and that levels of N-Myc RNA (the decoded form of a gene) from 137 patients with AML were between two- and 33-fold higher than in normal bone marrow cells.

The team also showed that myeloid cells that were genetically engineered to overexpress N-Myc became immortalized, or had an unlimited life span, and that this was associated with changes in levels of certain proteins known to occur when human myeloid cells become leukemic.

The St. Jude team demonstrated in cell cultures that N-Myc can also trigger apoptosis and kill the cell instead of making it reproduce uncontrollably. Specifically, most myeloid cells over-expressing N-Myc died within 24 hours when they were deprived of an anti-apotosis, growth-promoting protein called IL-3. In addition, there was a significant decrease in the activity of several other proteins that normally cooperate to prevent apoptosis -- a known effect of the protein made by N-Myc, Grosveld said.

The researchers then showed that mice that received bone marrow cells that were genetically engineered to overexpress N-Myc developed AML and died within 50 days.

Finally, Grosveld's team showed that the transformation of a myeloid cell to a leukemic cell requires overexpression of Twist, a gene that normally inhibits apoptosis.

"This work demonstrates the critical role N-Myc plays in AML and maps out the cooperation with other genes that blunt N-Myc's apoptotic effects, thereby tipping the delicate balance between cell death and cancer," Grosveld said.

Other authors of this report include Hiroyuki Kawagoe, Ayten Kandilci and Tanya Kranenburg (St. Jude).

This work was supported by the National Cancer Institute, a Cancer Center Support Grant and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit http://www.stjude.org.


'/>"/>
SOURCE St. Jude Children's Research Hospital
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: